ANTIFIBROSIS PEPTIDES AND THEIR APPLICATION IN METHODS OF TREATMENT OF DISEASES AND DISORDERS CHARACTERIZED BY FIBROSIS

摘要

1. A method of treating a subject having a disease or disorder characterized by fibrosis, comprising administering to the subject an effective amount of a peptide indicated as SEQ ID NO: 1-77, thereby treating the subject. The method of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1.3. The method according to p. 1, characterized in that the peptide has at least 90% identity to SEQ ID NO: 1.4. The method according to claim 1, characterized in that the peptide is mixed with a pharmaceutically acceptable carrier. The method of claim 1, wherein the peptide is administered orally to the subject. A method according to claim 1, characterized in that the peptide is administered to the subject locally, enterally or parenterally. The method of claim 1, wherein the disease or disorder is diabetic nephropathy, cirrhosis of the liver, idiopathic pulmonary fibrosis, rheumatoid arthritis, atherosclerosis, cardiac fibrosis, systemic sclerosis, nephritis and scleroderma. A method according to claim 1, wherein the disease or disorder is chronic renal failure (CKD). A method according to claim 1, characterized in that a dose of 0.0001 to 10,000 mg / kg of body weight is administered to the subject per day. The method according to claim 9, characterized in that the administered dose is from 1 to 100 mg / kg body weight per day. A peptide for the treatment of a disease or disorder characterized by fibrosis, comprising the amino acid sequence indicated as SEQ ID NO: 55.12. The peptide of claim 11, comprising the amino acid sequence indicated as any of SEQ ID NOs: l-77.13. The peptide according to claim 11, consisting of the amino acid sequence indicated as any of SEQ ID NOs: l-54.14. Pharmaceutical composition containing �